Manage & Schedule One on One Meetings

This year, the [15th World ADC San Diego] will be returning with One-on-One Partnering™! In [October], registered event attendees will be able to set up their company profile, update their calendar availability, and start requesting and accepting meetings.

Key Dates:
[Monday, October 7]

One-on-One Partnering opens for registered attendees

[Monday, October 14]

One-on-One Partnering scheduling begins

What To Expect

The [15th World ADC San Diego Summit] will offer all registered attendees access to One-on-One Partnering™, a tool for managing and pre-scheduling one-on-one meetings:

Find the Right Partners

Leverage our powerful search feature to find companies, delegates, assets, and markets for products or services. It’s a detailed catalogue of the most up-to-date partnering data, enabling you to find the best opportunities

Schedule Face-to-Face Meetings

Find the best times for your meetings and gain efficiency with automatic reminders and follow-up emails. Schedule meetings for all attendees whether they are physically present or not thanks to our hybrid capabilities.

Leverage Your Meeting

The history of your company's meetings at conferences hosted on One-on-One Partnering™ is at your fingertips. Know when you last met with a company, who attended and what messages were exchanged with our data archiving capabilities.

Collaborate with Colleagues

Work seamlessly as one team. View and modify your colleagues’ schedule, add them to meetings and share notes.

explore the agenda image
Explore the Agenda

Discover how the field’s leaders are redefining target selection, isotope pairing, and translational strategy to unlock the next era of radioligand therapy.

partner with us image
Partner With Us

Connect with RLT decision-makers searching for partners in targeting, imaging, radiochemistry, and isotopes to drive faster, safer radiopharmaceutical development.

join experts image
Join RLT Experts

Join 100+ radiochemists, biologists, drug designers, and R&D leaders advancing next-generation radioligand therapies from discovery through translation.